TL;DR
A pooled post-hoc analysis of two phase III trials found that postmenopausal women taking bedtime elinzanetant did not report increased daytime sleepiness over 12 weeks. Sleepiness scores fell more with the drug than with placebo, but the analysis was exploratory and does not establish that every patient will avoid next-day effects.
A pooled post-hoc analysis of two phase III trials found that postmenopausal women taking bedtime elinzanetant had lower daytime sleepiness scores over 12 weeks than women taking placebo, rather than an increase in next-day sleepiness. The findings, presented by Claudio Soares at the Menopause Society annual meeting, address a potential side effect for people using the nonhormonal drug for moderate to severe menopause-related hot flashes.
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
Researchers analyzed data from the OASIS I and OASIS II trials to examine daytime sleepiness and whether taking elinzanetant at bedtime was followed by residual sleepiness the next day. Elinzanetant is a dual neurokinin-1 and neurokinin-3 receptor antagonist. The analysis used seven-day averages of self-reported sleepiness scores, on a scale from zero, meaning not sleepy, to four, meaning very sleepy, and compared changes from the start of treatment to week 12.
Mean total sleepiness scores fell by 0.61 points with elinzanetant and 0.46 points with placebo, a mean difference of -0.15. Morning scores fell by 0.66 and 0.39 points, respectively, a difference of -0.27. Afternoon scores fell by 0.60 points with the drug and 0.45 with placebo. Evening scores changed by -0.56 and -0.54 points, a difference of -0.02. The report gave unadjusted 95% confidence intervals for these comparisons; the evening interval included no difference.
At baseline, average total sleepiness scores were 2.04 in the elinzanetant group and 1.94 in the placebo group. Participants also had moderate sleep disturbance on a separate patient-reported measure. By week 12, that measure had fallen by 10.7 points with elinzanetant and 5.3 points with placebo, with a reported P value below 0.0001. These sleep-disturbance results are distinct from the daytime sleepiness scores.
Daytime Alertness After Bedtime Dosing
For patients considering a treatment taken at night, possible next-day drowsiness can affect decisions about daily activities, including work and driving. The analysis offers preliminary reassurance that, on average, sleepiness scores did not worsen during the 12-week trial period and improved slightly more than with placebo. That matters because elinzanetant was associated in its OASIS trials with improvements in hot flashes and sleep disturbance, while dosing is recommended at bedtime.
The result should not be read as a guarantee that an individual patient will never feel sleepy or experience another side effect. The analysis measured reported sleepiness scores in trial participants; it does not establish effects in every patient, under all conditions, or beyond the periods studied. People taking the drug should follow their clinician’s advice and consult them if they notice effects that interfere with normal activities.
Products Worth Considering

Oral-B iO3 Rechargeable Electric Toothbrush with 3 Cleaning Modes, Pressure Sensor, 2 Brush Heads and Travel Case, White

Therabody TheraFace Cordless LED Light Therapy Mask

Withings Sleep Under-Mattress Sleep Tracking Pad
As an affiliate, we earn on qualifying purchases.
What the OASIS Trials Studied
OASIS I and II were phase III studies of elinzanetant in postmenopausal women with vasomotor symptoms, commonly called hot flashes. The original trials assessed the drug’s effects on the frequency and severity of symptoms, as well as sleep disturbance and menopause-related quality of life. The U.S. Food and Drug Administration approved elinzanetant for moderate to severe vasomotor symptoms due to menopause, according to the source report.
The daytime-sleepiness findings are a later, exploratory analysis of trial data, not the primary purpose of those studies. Elinzanetant is not indicated as a treatment for sleep disturbance, though it is recommended to be taken at bedtime. A previous phase I study also suggested no clinically relevant next-morning residual effect on simulated driving performance; that separate result is not the same as evidence from real-world driving.
“Patients treated with this medication, hoping to improve their vasomotor symptoms and sleep problems, can be reassured that they are unlikely to experience sleepiness the next day as an undesired, residual effect.”
— Claudio Soares, MD, PhD, of Queen’s University School of Medicine, speaking to MedPage Today
Limits of the Sleepiness Analysis
The results come from a post-hoc, exploratory analysis, and the report describes the confidence intervals as unadjusted. The available account does not provide the number of participants included in this specific analysis or enough detail to judge how the analysis handled all potential differences among participants. The score changes are averages, so they do not show whether some individuals experienced increased sleepiness.
It is also not clear from these findings how the results apply to people outside the trial populations, to longer-term use, or to patients taking other medicines that may affect alertness. The analysis did not establish that elinzanetant improves driving ability or prevents drowsiness in every user. The long-term OASIS-III findings on sleepiness have not yet been presented in the source report.
Long-Term Results Still Ahead
Soares and colleagues said they plan to present data from the longer-term OASIS III trial, which they said show similar trends in improved sleepiness, at a later date. Those findings may add information about whether the pattern continues with longer treatment, though they will need to be assessed on their own methods and results.
For now, the conference analysis adds a specific finding to the evidence on bedtime dosing: average reported daytime sleepiness did not increase over 12 weeks in the analyzed trial data. Patients should use elinzanetant as prescribed and discuss persistent drowsiness or concerns about daily functioning with a health professional.
Key Questions
What did the analysis find about next-day sleepiness?
In a pooled post-hoc analysis of OASIS I and II, average daytime sleepiness scores fell over 12 weeks among participants taking elinzanetant. The reductions were somewhat larger than with placebo, especially for morning scores. The findings do not rule out sleepiness in individual patients.
Is elinzanetant a medicine for insomnia?
No. The source report says elinzanetant is approved for moderate to severe menopause-related vasomotor symptoms and is not indicated to treat sleep disturbance. It is recommended to be taken at bedtime.
How large were the changes in sleepiness scores?
Mean total scores fell by 0.61 points with elinzanetant and 0.46 with placebo on a scale from zero to four. Morning scores fell by 0.66 and 0.39 points, respectively. These are group averages measured from baseline to week 12.
Does this mean the drug cannot cause drowsiness?
No. The analysis found no average increase in reported daytime sleepiness, but it cannot guarantee that no individual will feel drowsy. Anyone who experiences sleepiness that affects daily activities should contact their health professional.
What further evidence is expected?
The researchers said they plan to present sleepiness data from the longer-term OASIS III trial at a later date. The source report did not give a presentation date.
Source: rss
